迪哲醫藥(688192.SH):高瑞哲和DZD8586最新研究進展在歐洲血液學協會年會以及國際惡性淋巴瘤會議報告
格隆匯6月12日丨迪哲醫藥(688192.SH)公佈,公司將於2025歐洲血液學協會(EHA)年會和第18屆國際惡性淋巴瘤會議(ICML),公佈其血液腫瘤管線中的兩大全球首創(First-in-Class)新藥高瑞哲(通用名:戈利昔替尼膠囊)和DZD8586的重要研究進展。其中,高瑞哲針對經一線系統性治療後緩解的外周T細胞淋巴瘤(PTCL)維持治療的長期隨訪數據,以及DZD8586治療慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)的彙總分析成果,均將在ICML大會進行口頭報告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.